A share price of Ngm Biopharmaceuticals Inc [NGM] is currently trading at $1.91, saw in change for the day. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NGM shares have gain 28.19% over the last week, with a monthly amount glided 41.48%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, February 2024, NGM Bio to Participate in the Cowen 44th Annual Health Care Conference. In a post published today on Yahoo Finance, NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET.
From an analyst’s perspective:
Ngm Biopharmaceuticals Inc [NASDAQ: NGM] stock has seen the most recent analyst activity on May 03, 2023, when Citigroup initiated its Buy rating and assigned the stock a price target of $6. Previously, Raymond James downgraded its rating to Outperform on October 18, 2022, and dropped its price target to $4. On October 18, 2022, downgrade downgraded it’s rating to Neutral and revised its price target to $4 on the stock. Piper Sandler downgraded its rating to a Neutral. Jefferies downgraded its rating to a Hold. Jefferies started tracking with a Buy rating for this stock on July 20, 2022, and assigned it a price target of $25. In a note dated September 13, 2021, Raymond James upgraded an Strong Buy rating on this stock and boosted its target price from $27 to $39.
Ngm Biopharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $0.60 and $4.84. Currently, Wall Street analysts expect the stock to reach $16.5 within the next 12 months. Ngm Biopharmaceuticals Inc [NASDAQ: NGM] shares were valued at $1.91 at the most recent close of the market. An investor can expect a potential return of 763.87% based on the average NGM price forecast.
Analyzing the NGM fundamentals
Trailing Twelve Months sales for Ngm Biopharmaceuticals Inc [NASDAQ:NGM] were 22.43M which represents -92.64% decline. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8505 points at the first support level, and at 1.7909 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9898, and for the 2nd resistance point, it is at 2.0695.
Ngm Biopharmaceuticals Inc [NGM] reported earnings per share of -$0.35 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.42/share, meaning a difference of $0.07 and a surprise factor of 16.70%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.46 per share as compared to estimates of -$0.5 per share, a difference of $0.04 representing a surprise of 8.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ngm Biopharmaceuticals Inc [NASDAQ:NGM] is 7.92. In addition, the Quick Ratio stands at 7.92 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 7.04, the price to book ratio is 0.93.
Transactions by insiders
Recent insider trading involved COLUMN GROUP L P, Director, that happened on Nov 16 when 5840.0 shares were purchased. Director, COLUMN GROUP L P completed a deal on Nov 16 to buy 5840.0 shares. Meanwhile, Director COLUMN GROUP L P bought 5840.0 shares on Nov 16.
